48,466
edits
(fix) |
|||
(2 intermediate revisions by the same user not shown) | |||
Line 123: | Line 123: | ||
*EMA +ve ~100% (vs. ~10%). | *EMA +ve ~100% (vs. ~10%). | ||
*Desmin -ve ~5% (vs. ~85%). | *Desmin -ve ~5% (vs. ~85%). | ||
*GLUT1 +ve ~50% (vs. ~10%) | *GLUT1 +ve ~50% (vs. ~10%). | ||
*p53 +ve ~50% (vs. ~2%). | *p53 +ve ~50% (vs. ~2%). | ||
*BAP1 -ve<ref name=pmid29085180>{{cite journal |authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S |title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? |journal=Dis Markers |volume=2017 |issue= |pages=1310478 |date=2017 |pmid=29085180 |pmc=5612603 |doi=10.1155/2017/1310478 |url=}}</ref> ~57%.<ref name=pmid26226841>{{cite journal |authors=Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ |title=Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology |journal=Mod Pathol |volume=28 |issue=10 |pages=1360–8 |date=October 2015 |pmid=26226841 |pmc=4761613 |doi=10.1038/modpathol.2015.87 |url=}}</ref> | |||
Note: | Note: | ||
Line 140: | Line 141: | ||
**D2-40. | **D2-40. | ||
**[[CK5/6]]. | **[[CK5/6]]. | ||
*Carcinoma markers: | *Carcinoma markers: | ||
**CEA (monoclonal and polyclonal). | **CEA (monoclonal and polyclonal). | ||
Line 147: | Line 147: | ||
**MOC-31. | **MOC-31. | ||
**CD15. | **CD15. | ||
**[[B72.3]]. | |||
===Other carcinoma markers=== | ===Other carcinoma markers=== |
edits